The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Tyvense 30 mg Capsules, Hard

30 milligram(s) Capsule, hard

Shire Pharmaceuticals Ireland LimitedPA1575/005/002

Main Information

Trade NameTyvense 30 mg Capsules, Hard
Active SubstancesLisdexamfetamine dimesylate
Strength30 milligram(s)
Dosage FormCapsule, hard
Licence HolderShire Pharmaceuticals Ireland Limited
Licence NumberPA1575/005/002

Group Information



Licence Issued08/02/2013
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 of the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back